Pharmaceuticals, Biotechnology and Life Sciences
Dyno Therapeutics has entered collaboration with Novartis, to develop improved Adeno-Associated Virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases.
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients…
DUBLIN–(BUSINESS WIRE)–The “Global AI in Drug Discovery Market By Component (Software v/s Services), By Technology (Machine Learning, Deep Learning, Others),…
DUBLIN–(BUSINESS WIRE)–The “Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast – 2030” drug pipelines has been added…
BOSTON–(BUSINESS WIRE)–Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today…
Esteemed Leaders in Translation, Therapeutic Development and Critical Care Medicine TORONTO–(BUSINESS WIRE)–Vasomune Therapeutics, Inc., a therapeutic biopharmaceutical company developing a…
Reported positive top-line data from AXA1125-003, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation observed in…
Ms. Feldman is an experienced regulatory affairs leader with expertise in rare and neuromuscular disease WALTHAM, Mass.–(BUSINESS WIRE)–Dyne Therapeutics, a…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DrugDiscovery–The LG Chem Life Sciences Innovation Center and LabCentral, today announced a Gold sponsorship agreement including a Golden…
Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with…